Kymera Therapeutics, Inc. (KYMR) - Stock Analysis
Last updated: Apr 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Biotech momentum with nearâterm event: KYMR is up ~28% over 21 days with notable institutional accumulation (Baker Brothers, Rock Springs) and has its FY2025 results/earnings call on 2026â02â26; strong cash runway into 2028â2029 and positive early biomarker data support a speculative upside move if management reinforces timelines and clinical strategy.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠High cash burn ⢠Rich valuation As of 2025-12-31, KYMR has a very strong balance sheet and low leverage but is losing money, burning cash, and trading at an extreme valuation versus modest revenue while relying on financing to fund operations.
Price Behavior
Key Price Behavior Insights: ⢠Above last-month average ⢠Near recent high ⢠Higher lows intact Support Level: $79â$81 Resistance Level: $85.50â$86.00 KYMR is short-term bullishâtrading at $85.40 (â5.7% above its last month SMA) after a rally from $74.42, but near resistance at $85.5â$86 so a pullback or consolidation is possible;
Sentiment & News
Key News Insights: ⢠Firstâinâhuman dose ⢠Positive Phase 1b ⢠Mixed investor activity Kymera reported clinical momentum with firstâinâhuman IRF5 dosing and positive KTâ621 BroADen Phase 1b data, while investor activity was mixed with new institutional buys and insider stock sales.
AI Summary
Kymera has shifted into a catalystâdriven clinicalâexecution stock where KTâ621's midâstage readouts (midâ2026â2027) will largely determine valuation and the need for future dilutionâmonitor those readouts closely along with quarterly cash burn (watch if >~$200M/yr) and partner milestone receipts as the key triggers for upside or forced financing.
Description
Kymera Therapeutics develops small-molecule drugs that induce selective removal of disease-causing proteins by engaging the bodyâs native protein degradation pathways. Its pipeline includes an IRAK4 candidate in Phase I for several immuno-inflammatory conditions and programs targeting MYD88-mutant lymphoma, STAT3-related hematologic and solid tumors as well as autoimmune and fibrotic diseases, and MDM2-driven malignancies. The company was incorporated in 2015 and is based in Watertown, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 25 | Mar 4 | KYMR | Kymera Therapeutics, Inc. | Biotech momentum with nearâterm event: KYMR is up ~28% over 21 days with notable institutional accumulation (Baker Brothers, Rock Springs) and has its FY2025 results/earnings call on 2026â02â26; strong cash runway into 2028â2029 and positive early biomarker data support a speculative upside move if management reinforces timelines and clinical strategy. | Closed | -5.0% |